Jason Pitofsky
Known title: VP ControllerCIK: 0002009236
Associated companies
Transaction History
| REGN | ▲ Buy | Option Exercise | 1,000 | $492K | 2/9/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 20 | $16K | 2/9/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 521 | $405K | 2/9/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 563 | $438K | 2/9/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 205 | $160K | 2/9/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 75 | $59K | 2/9/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 26 | $20K | 2/9/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 37 | $29K | 2/9/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 144 | $113K | 2/9/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 1 | $785 | 2/9/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 53 | $42K | 2/9/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 391 | $304K | 2/9/2026 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 989 | $705K | 12/8/2025 | View on chart |
| REGN | ▲ Buy | Grant | 2,064 | $0 | 12/5/2025 | View on chart |
| REGN | ▼ Sell | Open Market | 431 | $281K | 11/7/2025 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 298 | $218K | 12/16/2024 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 149 | $117K | 12/9/2024 | View on chart |
| REGN | ▲ Buy | Grant | 907 | $0 | 12/6/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 487 | $521K | 8/7/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 487 | $181K | 8/7/2024 | View on chart |
| REGN | ▼ Sell | Gift | 90 | $0 | 4/29/2024 | View on chart |
| REGN | ▼ Sell | Gift | 89 | $0 | 4/4/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock
Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock. Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.